New therapeutic approaches for metastatic thyroid carcinoma
- 28 February 2007
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 8 (2), 148-156
- https://doi.org/10.1016/s1470-2045(07)70034-7
Abstract
No abstract availableThis publication has 59 references indexed in Scilit:
- Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivoClinical Cancer Research, 2006
- Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid CancerClinical Cancer Research, 2006
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogsTrends in Endocrinology & Metabolism, 2006
- Preventable reoperations for persistent and recurrent papillary thyroid carcinomaSurgery, 2004
- How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapyJournal of Endocrinology, 2004
- Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathwaysOncogene, 2004
- Gene Therapy for Thyroid Cancer: Current Status and Future ProspectsThyroid®, 2004
- Incidence of thyroid cancer in adults recorded by French cancer registries (1978–1997)European Journal of Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000